References
-
1
Altmann D, Eggmann U, Ammann P.
Medikamentös induzierte Verlängerung des QT-Intervalls.
Wien Klin Wochenschr.
2008;
120
128-135
-
2
Appleby M, Mbewu A, Clarke B.
Fluoxetine and ventricular rorsade – is there a link?.
Int J Cardiol.
1995;
49
178-180
-
3
Astrom-Lilja C, Odeberg JM, Ekman E. et al .
Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Pharmacoepidemiol Drug Safety.
2008;
17
587-592
-
4
Blaschke D, Parwani AS, Huemer M. et al .
Torsade de pointes during combined treatment with risperidone and citalopram.
Pharmacopsychiatry.
2007;
40
294-295
-
5
Brugisser M, Bravo A, Bodner M.
Medikamenten-assoziiertes Long-QT-Syndrom [Medication associated long QT syndrome].
Praxis.
2009;
98
1409-1415
-
6
de Gregorio C, Morabito G, Cerrito M. et al .
Citalopram-induced long QT syndrome and torsade de pointes: Role for committant therapies and illnesses.
Int J Cardiol.
2009;
DOI: doi:10.1016/j.ijcard.2009.05.060, available online
-
7
Gupta A, Lawrence AT, Krishnan K. et al .
Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
Am Heart J.
2007;
153
891-899
-
8
Hayes B, Klein-Schwarz W, Clark R. et al .
Comparison of toxicity of acute overdoses with citalopram and escitalopram.
J Emerg Med.
2008;
39
44-48
-
9
Isbister GK, Bowe SL, Dawson A. et al .
Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose.
J Toxicol Clin Toxicol.
2004;
42
277-285
-
10
Jimmink A, Caminada K, Ng H. et al .
Clinical toxicity of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases.
Ther Drug Monit.
2008;
30
365-371
-
11
Kanjanauthai S, Kanluen T, Charreonthaitawee P.
Citalopram induced torsade de pointes, a rare life threatening side effect.
Int J Cardiol.
2009;
131
333-334
-
12
Lherm T, Lottin F, Larbi D. et al .
[Torsades de pointes after poisoning with fluoxetine alone].
Presse Med.
2000;
29
306-307
(in French)
-
13
Meuleman C, Jourdain P, Bellorini M. et al .
Citalopram et torsades de pointes: A propos d'un cas [citalopram and torsades de pointes: A case report].
Archives des maladies du coeur et des vaisseaux.
2001;
94
1021-1024
(in French)
-
14
Sala M, Coppa F, Cappuciati C. et al .
Antidepressants: Their effects on cardiac channels, QT prolongation and torsade de pointes.
Curr Opin Investigational Drugs.
2006;
7
256-263
-
15
Tarabar A, Hoffman R, Nelson L.
Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest.
J Med Toxicol.
2008;
4
101-105
-
16
van Gorp F, Whyte I, GK I.
Clinical and ECG effects of escitalopram overdose.
Ann Emerg Med.
2009;
54
404-408
-
17
van Noord C, Straus SMJM, Sturkenboom MCJM. et al .
Psychotropic drugs associated with corrected QT interval prolongation.
J Clin Psychopharmacology.
2009;
29
9-15
-
18
Wilting I, Samals OM, Holwerda NJ. et al .
QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine.
Am J Psychiatry.
2006;
163
325
-
19
Witchel H, Pabbathi V, Hofmann G. et al .
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular calcium currents.
FEBS Lett.
2002;
512
59-66
-
20
Woosley RL.
Arizona CERT – QT Drug Lists by Risk Groups (accessed 10.6.2010), at.
http://www.azcert.org/med-prosl.cfm
Correspondence
K. Wenzel-SeifertMD
Institute of Pharmacology
Medical School of Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Germany
Phone: +49 511 532-2805/2806
Fax: +49 511 532-4081
Email: Wenzel-Seifert.Katharina@mh-hannover.de
